This study conducted by researchers from the National Institute on Drug Abuse (NIDA) found that patients receiving buprenorphine for opioid use disorder used cannabis less frequently than those on extended-release naltrexone. The findings suggest that buprenorphine may have a moderating effect on cannabis use, which could have implications for treatment strategies.
